GlobeNewswire: Karyopharm Therapeutics Contains the last 10 of 153 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:26:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/12/15/897954/0/en/Karyopharm-and-Collaborators-Awarded-Grant-for-ALS-Research.html?f=22&fvtc=4&fvtv=17815Karyopharm and Collaborators Awarded Grant for ALS Research2016-12-15T12:30:00Z<![CDATA[ - Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS -]]>https://www.globenewswire.com/news-release/2016/12/05/895281/0/en/Karyopharm-Presents-Updated-Phase-1b-STOMP-Data-at-the-American-Society-of-Hematology-2016-Annual-Meeting.html?f=22&fvtc=4&fvtv=17815Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting2016-12-05T22:45:00Z<![CDATA[- STOMP Data Continues to Demonstrate High Response Rates in Patients with Heavily Pretreated Multiple Myeloma When Selinexor Is Combined with Bortezomib and Pomalidomide -]]>https://www.globenewswire.com/news-release/2016/12/05/894872/0/en/Karyopharm-Presents-Updated-Phase-2b-STORM-Data-at-the-American-Society-of-Hematology-2016-Annual-Meeting.html?f=22&fvtc=4&fvtv=17815Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting2016-12-05T00:30:00Z<![CDATA[- Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -]]>https://www.globenewswire.com/news-release/2016/12/04/894868/0/en/Karyopharm-Presents-Updated-Phase-2-SAIL-Relapsed-Refractory-AML-Clinical-Data-at-the-American-Society-of-Hematology-2016-Annual-Meeting.html?f=22&fvtc=4&fvtv=17815Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting2016-12-04T17:30:00Z<![CDATA[- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia -]]>https://www.globenewswire.com/news-release/2016/11/30/893821/0/en/Karyopharm-and-the-Multiple-Myeloma-Research-Foundation-Announce-Panel-Discussion-Featuring-Leading-Multiple-Myeloma-Thought-Leaders.html?f=22&fvtc=4&fvtv=17815Karyopharm and the Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders2016-11-30T12:30:00Z<![CDATA[- Webcast Event Scheduled for Monday, December 5, 2016 at 8:15 PM PT - - Webcast Event Scheduled for Monday, December 5, 2016 at 8:15 PM PT -]]>https://www.globenewswire.com/news-release/2016/11/10/888784/0/en/Karyopharm-to-Present-at-the-Jefferies-2016-London-Healthcare-Conference.html?f=22&fvtc=4&fvtv=17815Karyopharm to Present at the Jefferies 2016 London Healthcare Conference2016-11-10T12:30:00Z<![CDATA[NEWTON, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Thursday, November 17, 2016 at 8:40 a.m. GMT. The conference will be held at the Waldorf Hilton in London.]]>https://www.globenewswire.com/news-release/2016/11/07/887494/0/en/Karyopharm-Reports-Third-Quarter-2016-Financial-Results-and-Highlights-Recent-Progress.html?f=22&fvtc=4&fvtv=17815Karyopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress2016-11-07T21:05:00Z<![CDATA[− Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Data Readout –]]>https://www.globenewswire.com/news-release/2016/11/03/886389/0/en/Karyopharm-to-Present-Updated-Phase-2b-STORM-and-Phase-1b-STOMP-Clinical-Data-at-the-American-Society-of-Hematology-2016-Annual-Meeting.html?f=22&fvtc=4&fvtv=17815Karyopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting2016-11-03T13:43:31Z<![CDATA[- Diverse Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -]]>https://www.globenewswire.com/news-release/2016/11/02/885636/0/en/Karyopharm-to-Ring-the-Nasdaq-Stock-Market-Closing-Bell.html?f=22&fvtc=4&fvtv=17815Karyopharm to Ring the Nasdaq Stock Market Closing Bell2016-11-02T11:30:00Z<![CDATA[Celebration Commemorating the Company’s 8th Anniversary Celebration Commemorating the Company’s 8th Anniversary]]>https://www.globenewswire.com/news-release/2016/10/31/884618/0/en/Karyopharm-to-Report-Third-Quarter-2016-Financial-Results-on-November-7-2016.html?f=22&fvtc=4&fvtv=17815Karyopharm to Report Third Quarter 2016 Financial Results on November 7, 20162016-10-31T11:30:00Z<![CDATA[Conference Call Scheduled for Monday, November 7, 2016 at 5:00 p.m. ET Conference Call Scheduled for Monday, November 7, 2016 at 5:00 p.m. ET]]>